肾癌药物市场：依疗法、按药理类别、按分销管道、按地区

2025 年全球肾癌药物市场规模估计为 73.1 亿美元，预计到 2032 年将达到 110.7 亿美元，2025 年至 2032 年的复合年增长率为 6.1%。

数字。 2025 年各地区肾癌药物市场占有率（%）

药物分析检测是指以科学的技术和方法确认肾癌（又称肾细胞癌）。肾癌正成为全球最常见的癌症之一。据估计，全球每年诊断出的新病例超过40万例。与肾癌相关的危险因子包括吸烟、肥胖、遗传因素和接触某些毒素。早期肾癌可能不会引起任何症状，但有些患者可能会出现尿液中带血、腰部疼痛或腹部肿块。治疗方案包括局部疾病的部分或根治性切除术、针对晚期疾病的标靶治疗和免疫治疗。总体而言，由于发病率上升、患者获得先进疗法的机会改善以及强大的新药管道等因素继续支撑市场成长，全球肾癌药物市场预计在未来几年将大幅增长。

市场动态：

全球肾癌药物市场受到全球肾细胞癌盛行率上升的推动。人口老化、肥胖率上升、职场毒素暴露增加等危险因子日益增多，导致了该病患病率的上升。此外，已开发国家患者获得优质标靶治疗和免疫疗法的机会的改善也支持了市场的成长。同时，手术、放射疗法和药物疗法结合的治疗週期更长，意味着患者越来越依赖维持治疗。虽然市场开发提供了有利可图的成长机会，但关键药物的专利到期和学名药市场进入等因素可能会扰乱大型开发商的收益来源。此外，新兴市场的高定价和可负担性问题限制了其进入更广泛的市场。然而，临床试验中针对各种疾病途径的分子管线非常强大，为未来的市场扩张提供了潜力。

本研究的主要特点

• 本报告对全球肾癌药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、绩效和策略等参数，介绍了全球肾癌药物市场的主要企业概况。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球肾癌药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员将透过用于分析全球肾癌药物市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球肾癌药物市场-冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 全球肾癌药物市场，依疗法分类，2020-2032 年（十亿美元）

• 标靶治疗
• 免疫疗法
• 化疗

6. 2020 年至 2032 年全球肾癌药物市场（依药理类别划分）（十亿美元）

• 血管新生抑制剂
• mTOR 抑制剂
• 细胞激素
• 其他（免疫查核点抑制剂、CTLA-4抑制剂、代谢拮抗剂等）

7. 2020-2032 年全球肾癌药物市场按通路划分（十亿美元）

• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年全球肾癌药物市场（按地区划分）（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • Pfizer Inc.
  • 3D Systems
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG（Genentech, Inc.）
  • Bayer AG
  • Exelixis, Inc.
  • Merck &Co., Inc.
  • Eisai Co., Ltd.
  • Aveo Pharmaceuticals
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

第 10 章分析师建议

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Kidney Cancer Drugs Market is estimated to be valued at USD 7.31 Bn in 2025 and is expected to reach USD 11.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Figure. Kidney Cancer Drugs Market Share (%), By Region 2025

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

• This report provides in-depth analysis of the global kidney cancer drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation-

• By Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
• By Pharmacological Class
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG (Genentech, Inc.)
  • Bayer AG
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Aveo Pharmaceuticals
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy
  • Market Snapshot, By Pharmacological Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Kidney Cancer Drugs Market, By Therapy, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Angiogenesis Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• mTOR Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cytokines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • 3D Systems
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Roche Holding AG (Genentech, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Exelixis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aveo Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact